Detalles de la búsqueda
1.
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.
Blood
; 140(12): 1378-1389, 2022 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35737911
2.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol
; 103(2): 437-442, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38060001
3.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Cancer
; 129(7): 992-1004, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36692409
4.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood
; 137(22): 3027-3036, 2021 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739404
5.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608183
6.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
7.
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol.
Haematologica
; 106(7): 1828-1838, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33538150
8.
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 100(2): 429-436, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33161453
9.
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
Haematologica
; 105(1): 193-200, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31221778
10.
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Eur J Haematol
; 104(5): 435-442, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31883396
11.
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
Eur J Haematol
; 104(6): 581-587, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107795
12.
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
Oncologist
; 24(9): 1246-1252, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30940746
13.
Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
Ann Hematol
; 98(6): 1449-1455, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30868307
14.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Ann Hematol
; 98(2): 361-367, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353388
15.
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Biol Blood Marrow Transplant
; 24(9): 1814-1822, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29857196
16.
Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 97(10): 1817-1824, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30054707
17.
Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.
J Thromb Thrombolysis
; 46(2): 174-179, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29737462
18.
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Lancet Oncol
; 18(8): 1076-1088, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28668386
19.
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.
Biol Blood Marrow Transplant
; 23(7): 1102-1109, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28390983
20.
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Br J Haematol
; 172(1): 111-21, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26458240